Qyuns Therapeutics (Stock Code: 2509) has released an announcement regarding continuing connected transactions linked to its QX001S Framework Agreement with Zhongmei Huadong. Previously, annual caps were established for 2024 and 2025; now, the company intends to renew these caps for 2026, 2027, and 2028. Under the existing arrangements, the QX001S Supply Agreement and Supplemental Agreements cover key areas such as product supply and profit sharing.

In explaining this renewal, the board cites the commercialization progress of SAILEXIN (QX001S), which received its first approval from the relevant regulatory authority in 2024 and has continued to expand through supplemental applications for pediatric plaque psoriasis and Crohn’s disease. According to the announcement, the growing market demand and sales potential are core drivers behind the plan to increase the annual caps for product supply and profit sharing in the coming years.

The announcement highlights that Zhongmei Huadong holds 15.85% of the issued share capital of Qyuns Therapeutics (excluding shares held by the company as treasury shares), classifying it as a connected person under the Listing Rules. Because certain percentage ratios exceed 5%, these transactions are subject to reporting, announcement, annual review, and independent shareholders’ approval. The extraordinary general meeting (EGM) will be convened to seek approval for renewing the caps, with Zhongmei Huadong and its associates required to abstain from voting on the relevant resolutions.

Separately, Qyuns Therapeutics proposes amending the Articles of Association by updating share capital details. This amendment also awaits shareholder approval during the coming EGM. A circular containing further specifics, including the independent board committee’s recommendations and an independent financial adviser’s opinions, is expected to be dispatched on or about December 4, 2025.